Results 81 to 90 of about 13,748 (197)

Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG‐TOP2 Study

Cancer Science, Volume 117, Issue 2, Page 522-535, February 2026.
In the JCCG‐TOP2 nationwide pediatric cancer genomic profiling study, 204 patients' tumors and peripheral blood from 50 institutions across Japan were successfully analyzed using a dual DNA/RNA panel. A total of 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%),
Kayoko Tao, Takako Yoshioka, Miho Kato, Kazuyuki Komatsu, Shinichi Tsujimoto, Kenichi Sakamoto, Kazuki Tanimura, Minako Sugiyama, Masahiro Sekiguchi, Yoshiko Nakano, Yoshihiro Otani, Yasushi Yatabe, Akihiko Yoshida, Hajime Okita, Junko Hirato, Kenichi Kohashi, Yukichi Tanaka, Shinji Kohsaka, Takashi Kubo, Kuniko Sunami, Makoto Hirata, Shuichi Tsutsumi, Hiroyuki Aburatani, Katsuyoshi Koh, Masahiro Hirayama, Shuhei Karakawa, Yukayo Terashita, Hiroyuki Fujisaki, Takeshi Yagi, Akihiro Yoneda, Shinji Mochizuki, Hiroyuki Shichino, Tatsuya Suzuki, Tetsuya Takimoto, Koichi Ichimura, Chitose Ogawa, Kimikazu Matsumoto, Hitoshi Ichikawa, Motohiro Kato   +38 more
wiley   +1 more source

NTRK gene aberrations in triple‐negative breast cancer: detection challenges using IHC, FISH, RT‐PCR, and NGS

The Journal of Pathology: Clinical Research, 2023
Triple‐negative breast cancer (TNBC) is usually an aggressive disease with a poor prognosis and limited treatment options. The neurotrophic tyrosine receptor kinase (NTRK) gene fusions are cancer type‐agnostic emerging biomarkers approved by the Food and
Federica Zito Marino, Simona Buono, Marco Montella, Rosa Giannatiempo, Francesco Messina, Giovanni Casaretta, Grazia Arpino, Giulia Vita, Francesco Fiorentino, Luigi Insabato, Alessandro Sgambato, Michele Orditura, Renato Franco, Marina Accardo   +13 more
doaj   +1 more source

WHO classification of skin tumours: key updates in the fifth edition

Histopathology, Volume 88, Issue 3, Page 555-568, February 2026.
This review article summarizes the key updates in the 5th edition of the WHO Classification of Skin Tumours. It provides an overview of the major changes and new entities specific to the skin section, covering areas such as epidermal, melanocytic, mesenchymal and other tumours. The 5th edition of the World Health Organization Classification of Tumours (
Gabrielle Goldman‐Lévy, Raymond Barnhill, Boris C. Bastian, Werner Kempf, David Elder, Pedram Gerami, Wayne Grayson, Dmitry Kazakov, Daniela Massi, Jane Messina, Arnaud de la Fouchardière, Alexander J. Lazar, Thomas Brenn, Brian Rous, Andrew Field, Anthony Gill, Jennelle C. Hodge, Joseph D Khoury, Katia Leite, Shahin Sayed, Puay Hoon Tan, Rosalie Elenitsas, Eduardo Calonje, Lyn M. Duncan, Liang Zhiyong, Holger Moch, Rajendra Singh, Harshima Wijesinghe, Ian Cree, Dilani Lokuhetty   +29 more
wiley   +1 more source

Longitudinal correlations in the initial stages of ultra-relativistic nuclear collisions [PDF]

, 2016
In this talk we review some of our results for the longitudinal correlations in connection with recent experimental data, in particular for the {\em torque} effect and for the two-particle correlations in pseudorapidity, $C(\eta_1,\eta_2)$.
Bozek, Piotr, Broniowski, Wojciech
core   +2 more sources

CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas

American Journal of Hematology, Volume 101, Issue 1, Page 110-128, January 2026.
ABSTRACT The tumor necrosis factor (TNF)‐receptor superfamily 8 receptor CD30 molecule is expressed in all tumor cells of Hodgkin lymphoma and anaplastic large cell lymphoma but is only weakly expressed in a small subset of large lymphoid cells in normal peripheral lymphoid tissues.
Harald Stein, Brunangelo Falini
wiley   +1 more source

Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours

Scientific Reports, 2023
NTRK gene fusions are rare somatic mutations found across cancer types with promising targeted therapies emerging. Healthcare systems face significant challenges in integrating these treatments, with uncertainty in prevalence and optimal testing methods ...
Sophie O’Haire, Fanny Franchini, Yoon-Jung Kang, Julia Steinberg, Karen Canfell, Jayesh Desai, Stephen Fox, Maarten IJzerman   +7 more
doaj   +1 more source

Measurement of the hadronic photon structure function F_{2}^{γ} at LEP2 [PDF]

, 2002
The hadronic structure function of the photon F_{2}^{γ} (x, Q²) is measured as a function of Bjorken x and of the photon virtuality Q² using deep-inelastic scattering data taken by the OPAL detector at LEP at e⁺e⁻ centre-of-mass energies from 183 to 209 ...
Abbiendi, G, Ainsley, C, Alexander, G, Allison, J, Anagnostou, G, Anderson, KJ, Asai, S, Axen, D, Azuelos, G, Bailey, I, Barberio, E, Barlow, RJ, Batley, RJ, Bechtle, P, Behnke, T, Bell, KW, Bell, PJ, Bella, G, Bellerive, A, Benelli, G, Bethke, S, Biebel, O, Bloodworth, IJ, Bock, P, Boeriu, O, Bonacorsi, D, Boutemeur, M, Braibant, S, Brigliadori, L, Brown, RM, Buesser, K, Burckhart, HJ, Cammin, J, Campana, S, Carnegie, RK, Caron, B, Carter, AA, Carter, JR, Chang, CY, Charlton, DG, Cohen, I, Csilling, A, Cuffiani, M, Dado, S, Dallavalle, GM, Dallison, S, De Roeck, A, De Wolf, EA, Desch, K, Donkers, M, Dubbert, J, Duchovni, E, Duckeck, G, Duerdoth, IP, Etzion, E, Fabbri, F, Feld, L, Ferrari, P, Fiedler, F, Fleck, I, Ford, M, Frey, A, Fürtjes, A, Gagnon, P, Gary, JW, Gaycken, G, Geich-Gimbel, C, Giacomelli, G, Giacomelli, P, Giunta, M, Goldberg, J, Gross, E, Grunhaus, J, Gruwé, M, Gupta, A, Günther, PO, Hajdu, C, Hamann, M, Hanson, GG, Harder, K, Harel, A, Harin-Dirac, M, Hauschild, M, Hauschildt, J, Hawkes, CM, Hawkings, R, Åkesson, PF   +86 more
core  

New Measurements of Upsilon(1S) Decays to Charmonium Final States

, 2004
Using substantially larger data samples collected by the CLEO III detector, we report on new measurements of the decays of Upsilon(1S) to charmonium final states, including J/Psi, psi(2S), and chi_cJ. The latter two are first observations of these decays.
A. Bornheim, A. H. Mahmood, A. J. Sadoff, A. J. Weinstein, A. Lopez, A. Ryd, A. Smith, A. Tomaradze, A. W. Scott, B. Gittelman, B. I. Eisenstein, B. K. Heltsley, B. Sanghi, C. Boulahouache, C. D. Jones, C. J. Stepaniak, C. S. Park, C. Sedlack, D. Besson, D. Cinabro, D. Cronin-Hennessy, D. G. Cassel, D. H. Miller, D. Hertz, D. Kim, D. L. Hartill, D. L. Kreinick, D. M. Asner, D. Peterson, D. Riley, D. T. Gong, D. Urner, E. Dambasuren, E. H. Thorndike, E. I. Shibata, E. Lipeles, F. Liu, G. Bonvicini, G. D. Gollin, G. P. Chen, G. S. Adams, G. S. Huang, G. Tatishvili, H. Albrecht, H. Mahlke-Krüger, H. Mendez, H. Muramatsu, H. Schwarthoff, H. Severini, H. Stoeck, H. Vogel, I. Danko, I. Karliner, I. P. J. Shipsey, J. A. Mueller, J. B. Thayer, J. Butt, J. C. Wang, J. E. Duboscq, J. Ernst, J. G. Thayer, J. J. Thaler, J. Kandaswamy, J. L. Rosner, J. Napolitano, J. P. Alexander, J. P. Cummings, J. Pivarski, J. R. Patterson, J. Ramirez, J. Urheim, J. Williams, J. Wiss, J. Yelton, K. Arms, K. Berkelman, K. K. Gan, K. K. Seth, K. M. Ecklund, K. W. Edwards, K. Y. Gao, K. Zhang, L. Breva-Newell, L. Fields, L. Gibbons, L. Hsu, M. Artuso, M. Chasse, M. Dubrovin, M. E. Watkins, M. Kobayashi, M. R. Shepherd, M. Selen, M. Weinberger, N. E. Adam, N. Lowrey, N. Menaa, O. Dorjkhaidav, P. Avery, P. Naik, P. Rubin, P. Skubic, P. U. E. Onyisi, P. Zweber, R. A. Briere, R. Ehrlich, R. Gray, R. Mountain, R. Nandakumar, R. Patel, R. Poling, R. Redjimi, R. S. Galik, R. Sia, R. Stroynowski, S. A. Dytman, S. B. Athar, S. Baek, S. Blusk, S. E. Csorna, S. Mehrabyan, S. P. Pappas, S. Stone, S. W. Gray, S. Z. Li, T. E. Coan, T. Ferguson, T. O. Meyer, T. Skwarnicki, T. Wilksen, V. E. Kuznetsov, V. Pavlunin, V. Potlia, V. Savinov, W. M. Sun, W. Park, Y. Kubota, Y. S. Gao, Z. Li, Z. Metreveli   +139 more
core   +1 more source

Melanoma: Pathogenesis and Targeted Therapy

MedComm, Volume 7, Issue 1, January 2026.
The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu, Jie Liu, Zeming Mo, Bin Wang, Yaotiao Deng, Yu Jiang   +5 more
wiley   +1 more source

How I treat NTRK gene fusion-positive cancers [PDF]

ESMO Open, 2019
NTRK fusions are found at low frequencies (commonly
openaire   +4 more sources